NervGen Pharma: Restatement Expected to Reduce Previously Reported Stock-Based Compensation Expense >NGEN

Dow Jones2026/09/25 20:33

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Morgan Stanley Names 3 Biotech Breakthroughs That Offer Investment Opportunities

BeInCrypto•2026/10/01 04:27

Is Oura's IPO Delay About Markets or Its $15 Billion Valuation?

BeInCrypto•2026/10/01 03:45

Meta Used Zuckerberg's Pay to Cut Its Taxes by $355 Million: Could Musk Do It Too?

BeInCrypto•2026/09/30 23:33

SUI crypto hits 6B transaction blocks, but rising funding flashes a warning

AMBCrypto•2026/09/30 21:33